Optogenetic RP Therapy Gains RMAT - Takeaway - MDSpire
From the Journals
Feature

Optogenetic RP Therapy Gains RMAT

Ray Therapeutics secures FDA RMAT designation for its optogenetic retinitis pigmentosa therapy

  • April 29, 2026

  • 2 min

Share

  • 1

    Ray Therapeutics received RMAT designation from FDA for RTx-

  • 2

    RTx-015 targets retinitis pigmentosa by restoring visual function.

  • 3

    Administered via single intravitreal injection; bypasses degenerated photoreceptors.

  • 4

    Aiming to change treatment strategies from slowing progression to restoring vision.

  • 5

    The therapy supports real-world endpoints reflecting visual function and quality of life.

  • 6

    Broader pipeline includes RTx-021 targeting macular diseases.

  • 7

    Optogenetics offers mutation-agnostic solutions for retinal degeneration.

Original Source(s)

Optogenetic RP Therapy Gains RMAT

  • April 29, 2026

Related Content

Japan Debuts Novel Dry Eye Therapy

Senju Pharmaceutical launches the first TRPV1 antagonist for dry eye in Japan

  • April 30, 2026

  • 3 min
Why Smart Eye Surgeons Still Make Bad Growth Decisions

You’re not making poor decisions; you’re being forced to decide without clear, trustworthy data across your patient journey

The New Era of Postoperative Inflammation Management

What surgeons need to know about managing post-cataract inflammation